TLR8

GSK3528869A (Bepirovirsen) for Chronic Hepatitis B Drug Pipeline Research 2024: Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 18, 2024
Research, Infectious Diseases, Chemicals, Plastics, Clinical Trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, Hepatocyte, Protein, SWOT, Hepatitis, TLR8, EU4, Group C, RNA, Toll-like receptor 8, Disease, MPL, GSK, Hepatitis B virus, HBcAg, Immune system, Clinical trial, HBV, Vaccine

The report provides comprehensive insights about GSK3528869A Bepirovirsen for chronic hepatitis B in the seven major markets and China.

Key Points: 
  • The report provides comprehensive insights about GSK3528869A Bepirovirsen for chronic hepatitis B in the seven major markets and China.
  • Other emerging products for chronic hepatitis B are expected to give tough market competition to GSK3528869A Bepirovirsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GSK3528869A Bepirovirsen in chronic hepatitis B.
  • What are the other emerging products available and how are these giving competition to GSK3528869A Bepirovirsen for chronic hepatitis B?

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Retrieved on: 
Wednesday, April 19, 2023
NOD2, AACR, Therapy, Neoplasm, Cancer, American Association for Cancer Research, TLR9, NSAID, Breast, Research, LDC, TLR4, TLR2, Patient, NLR, TLR8, Poster, Metastasis, Pharmaceutical industry, Vaccine

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.

Key Points: 
  • NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform.
  • The poster, titled, “ A systemically administered killed bacteria-based multiple immune receptor agonist for pulsed anti-tumor immunotherapy ,” authored by Michael J. Newman, Ph.D., the Company’s Founder and Chief Scientific Officer, was presented Tuesday, April 18, 2023.
  • Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody.
  • Importantly, our results demonstrate the potential for activity in multiple solid tumor indications with high unmet need and the flexibility to be combined with a wide variety of synergy partners.

Zhimeng Biopharma will report positive phase 1b trial results on its HBV capsid inhibitor ZM-H1505R in the upcoming International Liver Congress

Retrieved on: 
Tuesday, June 14, 2022
Cmin, EASL, NA, Pharmacokinetics, Plasma, CEO, Viremia, ZM, AE, Patient, HBV, DNA, Lists of diseases, TLR8, SAE, Virus, Hepatitis, CHB, Safety, Pharmaceutical industry

SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase 1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress in June 22-26, 2022 (the EASL meeting).

Key Points: 
  • SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase 1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress in June 22-26, 2022 (the EASL meeting).
  • ZM-H1505R was safe and well tolerated within this dose range, with most AEs being mild to moderate in severity.
  • Serum levels of HBV DNA and HBV pgRNA were significantly reduced from baselines after 28 days of treatment with ZM-H1505R.
  • "We are pleased to see the positive safety and preliminary efficacy results of ZM-H1505R from this phase 1b study."

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 12, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Risk, Disease, Toxicity, HBV, Research, U.S. Securities and Exchange Commission, Nasdaq, News, Patient, Hepatitis, Investment, Antibody, Hand, Therapy, CFBV, Liver, Â, ASGR1, TLR8, Program, Safety, Security (finance), Cancer, Gastrointestinal tract, Vaccine, Gorilla

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Initiated Phase 1-enabling toxicology study for SBT8230 in the first quarter of 2022 and on track to complete Phase 1 regulatory submission in the fourth quarter of 2022.
  • Silverback continues to advance discovery programs, with an update anticipated in the fourth quarter of 2022.
  • For the first quarter ended March 31, 2022, Silverback reported a net loss of $24.6 million, compared to a net loss of $18.9 million for the comparable period in 2021.

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, March 31, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Risk, Therapy, TLR8, Investment, Liver, Research, Serum, Program, Conference, Cancer, U.S. Securities and Exchange Commission, ASGR1, Workforce, Hand, Safety, Nasdaq, Myelocyte, News, Blood, Insurance, Seroconversion, Patient, Disease, Pembrolizumab, Security (finance), Vaccine, Pharmaceutical industry, Animal, Gorilla, Webcast

We continue to advance SBT8230 and are on track to complete a Phase 1 regulatory submission in the fourth quarter of 2022.

Key Points: 
  • We continue to advance SBT8230 and are on track to complete a Phase 1 regulatory submission in the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter ended December 31, 2021 were $15.9 million, compared to $8.8 million for the same period in 2020.
  • Silverback also incurred additional personnel-related expenses in 2021 as compared to 2020 as operations grew in support of program advances.
  • General and administrative expenses for the fourth quarter ended December 31, 2021 were $7.6 million, compared to $4.3 million for the same period in 2020.

Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, Pharmaceutical, Health, Cancer, Nasdaq, Conference, Therapy, Tumor microenvironment, Gorilla, TLR8, Disease, Vaccine

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.
  • Laura Shawver, Ph.D., Silverbacks Chief Executive Officer, will present a corporate overview on Wednesday, March 9th, 2022, at 12:50 p.m.
  • Members of the Silverback management team will also host investor meetings during the conference.
  • Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Retrieved on: 
Thursday, February 3, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Gorilla, Therapy, SVB, Cancer, TLR8, Disease, Tumor microenvironment, Conference, Nasdaq, Vaccine

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022.
  • The live webcast of the event will be available on Silverbacks Investor Relations website and a replay will be available for 30 days following the event.
  • Members of the Silverback management team will also host investor meetings during the conference.
  • Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Silverback News (SBTX); Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel

Retrieved on: 
Monday, January 10, 2022
IPO, LLP, SAN, NASDAQ, Learning, Class, Company, Lists of schools in England, TLR8, Breast, Neoplasm, GLOBE, Pharmaceutical industry, Gorilla

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX) against certain of its officers and directors.

Key Points: 
  • SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX) against certain of its officers and directors.
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • If you are interested in learning more about the investigation, please contact lead analyst Jim Baker ( [email protected] ) at 619-814-4471.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.

Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Nasdaq, Disease, Tumor microenvironment, Cancer, TLR8, Gorilla, Conference, Vaccine

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.
  • Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
  • Silverbacks platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.
  • Silverback Therapeutics is located in Seattle, Washington.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Silverback Therapeutics, Inc., of Class Action Lawsuit and Upcoming Deadline – SBTX

Retrieved on: 
Tuesday, January 4, 2022
ESMO, Lists of action films, Pomerantz, Securities Act of 1933, Company, Therapy, Court, Patient, European Society for Medical Oncology, Lists of schools in England, Cancer, Breast, Securities Exchange Act of 1934, Gorilla, Oncology, Neoplasm, IPO, NASDAQ, Person, LLP, Complaint, Defendant, Class, News, Ext, GLOBE, TLR8, District court, Security (finance)

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Silverback, a clinical-stage biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.